Stockscreener 앱 받기
14.11
3.52%
0.48
시간 외 거래:
14.00
-0.11
-0.78%
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
When the Price of (ARQT) Talks, People Listen - news.stocktradersdaily.com
ARQT: Key Insights from Genital Psoriasis Consensus Statements | - GuruFocus
New Consensus Statements on Impact of Genital Psoriasis on Patie - GuruFocus
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice - The Manila Times
Arcutis Biotherapeutics Publishes Expert Consensus on Genital Psoriasis to Enhance Patient Care and Treatment Decision-Making - Nasdaq
Medical Breakthrough: Experts Release 14 Game-Changing Guidelines for Genital Psoriasis Treatment - Stock Titan
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy - openPR.com
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics - Barchart.com
Director’s Bold Move: A Major Investment in Arcutis Biotherapeutics - TipRanks
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and AMN Healthcare Services (AMN) - The Globe and Mail
Arcutis outlines growth potential with ZORYVE expansions and market penetration - MSN
Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates - MSN
Arcutis Biotherapeutics: Zoryve foam treatment resulted in major improvements - Yahoo Finance
Arcutis Biotherapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2025 Earnings Call Transcript - Insider Monkey
Arcutis Biotherapeutics Reports Strong Q1 Earnings Growth - TipRanks
Jefferies lifts Arcutis stock target to $20 on strong sales By Investing.com - Investing.com South Africa
ZORYVE foam shows promise in psoriasis treatment By Investing.com - Investing.com South Africa
ZORYVE foam shows promise in psoriasis treatment - Investing.com
Arcutis Announces Publication of Positive Data from ARRECTOR Tri - GuruFocus
Arcutis Biotherapeutics (ARQT) Reports Positive Phase 3 Trial Results for Psoriasis Treatment | ARQT Stock News - GuruFocus
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology - The Manila Times
Arcutis Announces Publication of Positive Data from Arrector Trial Evaluating Zoryve®? (Roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology - marketscreener.com
Jefferies lifts Arcutis stock target to $20 on strong sales - Investing.com Australia
Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Decoding Arcutis Biotherapeutics Inc (ARQT): A Strategic SWOT In - GuruFocus
Arcutis Biotherapeutics Reports Strong Q1 2025 Growth - TipRanks
Arcutis (ARQT) Reports Strong Q1 Growth on Rising ZORYVE Demand - GuruFocus
Earnings call transcript: Arcutis Biotherapeutics Q1 2025 earnings beat estimates - Investing.com
Earnings call transcript: Arcutis Biotherapeutics Q1 2025 earnings beat estimates By Investing.com - Investing.com India
Arcutis Biotherapeutics stock falls despite Q1 revenue beat By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics stock falls despite Q1 revenue beat - Investing.com
Arcutis Biotherapeutics (ARQT) Q1 Performance Surpasses Expectations - GuruFocus
Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings: EPS Loss of $0.20 Beats Estimate, Revenue Surpasses Forecast at $63.8 Million - GuruFocus
Arcutis Q1 2025 slides: Revenue soars 196% YoY despite seasonal headwinds - Investing.com India
ARCUTIS BIOTHERAPEUTICS Earnings Results: $ARQT Reports Quarterly Earnings - Nasdaq
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Arcutis Biotherapeutics (ARQT) Surpasses Q1 Revenue Expectations with Robust Growth | ARQT Stock News - GuruFocus
Earnings Flash (ARQT) Arcutis Biotherapeutics Reports Q1 Revenue $65.8M, vs. FactSet Est of $62.2M - marketscreener.com
Arcutis Q1 Earnings: ZORYVE Sales Surge 196% to $64M as Coverage Expands | ARQT Stock News - Stock Titan
Arcutis Biotherapeutics (ARQT) Q1 Earnings Preview - GuruFocus
How to Take Advantage of moves in (ARQT) - news.stocktradersdaily.com
What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q1 2025 E - GuruFocus
Chronic Hand Eczema Pipeline 2025: FDA Approvals, Therapies, - openPR.com
What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings - GuruFocus
1.54%
7.58%
자본화:
|
볼륨(24시간):